Zoledronic acid in adjuvant therapy of receptor negative early breast cancer - Rationale and first experience in individual therapy strategy;Zoledronat in der adjuvanten therapie des rezeptornegativen mammakarzinoms - Rationale und erfahrungen mit einzelfallentscheidungen

Geburtshilfe und Frauenheilkunde

Volumn 71, Issue 2, 2011, Pages 135-139

  Paepke, S ^a   Blohmer, J U ^b   Warm, M ^c   Ohlinger, R ^d   Kiechle, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Brustzentrum City Im St Gertraudenkrankenhaus Berlin Wilmersdorf ^*  (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

adjuvant therapy; case discussion; therapy recommendation; triple negative breast cancer; zoledronate

Indexed keywords

ESTROGEN RECEPTOR; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; EARLY CANCER; HUMAN;

EID: 79951951708     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0030-1250685     Document Type: Article

References (31)

1. Saad F. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007 110 1860-1867
2. Winter M C., Holen I, Coleman R E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008 34 453-475
3. Santini D, Martini F, Fratto M E. et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009 58 31-38
4. Wood J, Schnell C, Green J R. Zoledronic acid (Zometa), a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. In: ASCO Annual Meeting 2000, Program/Proceedings Abstracts, Vol. 19. Pp. Abstr. 2620.
5. Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007 13 4482-4486
6. Senaratne S G., Pirianov G, Mansi J L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000 82 1459-1468
7. Jagdev S P., Coleman R E., Shipman C M. et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001 84 1126-1134
8. Costa L, Major P P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009 15 163-174
9. Diel I J., Solomayer E F., Costa S D. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 339 357-363
10. Diel I J., Jaschke A, Solomayer E F. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long-term follow-up. Ann Oncol 2008 19 2007-2011
11. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006 8 R13
12. Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001 19 10-17
13. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009 360 679-691
14. Coleman R, Bundred N, De Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Poster presented at 32th SABCS, December 9-13, 2009; San Antonio, Texas USA; #4082.
15. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000 60 2949-2954
16. Rachner T D., Singh S K., Schoppet M et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010 287 109-116
17. Hiraga T, Williams P J., Ueda A et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Cancer Res 2004 10 4559-4567
18. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005 22 195-201
19. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010 11 421-428
20. Lin Y, Park J W., Scott J et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008 26 559-559
21. ASCO Annual Meeting Proceedings]; 26 (15S): 559
22. Rack B, Schindlbeck C, Strobl B et al. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008 133 285-289
23. Solomayer E, Gebauer G, Hirnle P et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Research 2009 69 (Suppl. 2) 170s-171s
24. Rack B K., Schindlbeck C, Schneeweiss A et al. Persistance of circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis. J Clin Oncol 2009 27 (15S) Abstr 554-Abstr 554
25. Neville-Webbe H L., Rostami-Hodjegan A, Evans C A. et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostata cancer cells. Int J Cancer 2005 20: 113 364-371
26. Brubaker K D., Brown L G., Vessella R L. et al. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006 6 15-15
27. Neville-Webbe H L., Evans C A., Coleman R E. et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006 27 92-103
28. Ottewell P D., Woodward J K., Lefley D V. et al. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009 8 2821-2832
29. Coleman R E., Winter M C., Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010 102 1099-1105
30. Empfehlungen der AGO, Stand 2010. http://www.agoonline.de/-download/ unprotected/g-mamma-10-1-0-d-26-bisphosphonates.pdf
31. Rastogi P, Anderson S J., Bear H D. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol 2008 26 778-785